A recent study published in HemaSphere delves into the intricate dynamics of chronic lymphocytic leukemia (CLL) cells within the tumor microenvironment (TME), shedding light on how they manipulate their surroundings to bolster resistance to therapy and drive disease progression. By leveraging a sophisticated human 3D cell culture model that closely emulates bone marrow niches in vivo, researchers uncovered a collaborative strategy between CLL B cells, autologous T cells, and bone marrow-derived stromal cells (BMSCs) to activate the AP-1 transcription factor complex. This activation confers survival advantages upon the CLL cells, emphasizing the critical role of the TME in shaping disease outcomes.
Within the 3D scaffold, CLL B cells exhibited varying degrees of survival advantage depending on their location, with those in the core regions displaying enhanced resistance to cell death compared to their counterparts in the periphery. The study highlights the significant proportion of B and T cells in different compartments of the 3D culture, with core B cells demonstrating superior survival rates and heightened resistance to therapeutic agents. Notably, T-cell phenotyping revealed a distinct population in the core regions characterized by both activation and exhaustion markers, underscoring the intricate interplay between different immune cell subsets within the TME.
By isolating CLL B cells from core and peripheral zones for bulk RNA sequencing, researchers identified a substantial upregulation of genes associated with survival, immune regulation, and cell adhesion in core-localized CLL cells. Notably, the AP-1 transcription factor family emerged as a key player in driving cell proliferation and therapy resistance, suggesting its potential as a therapeutic target in CLL. Further exploration through single-cell RNA sequencing of BMSCs exposed to CLL cells unveiled a unique subpopulation termed contact-induced BMSCs (ciBMSCs), characterized by distinct gene expression profiles enriched in immunosuppressive and inflammation-related genes, offering insights into the mechanisms underpinning stromal reprogramming in CLL.
The study’s findings underscore the promise of AP-1 inhibition as a strategy to disrupt the protective niches within the TME. Treatment with specific AP-1 inhibitors led to increased apoptosis in core CLL cells, with the combination of inhibitors showing the most pronounced effect. Importantly, AP-1 inhibition also downregulated key molecules involved in immune suppression, such as PD-L1 and WLS, in BMSCs, highlighting the potential for targeting both malignant cells and the reprogrammed stromal compartment to enhance therapeutic outcomes in CLL. The research provides critical insights into the cellular organization and molecular mechanisms driving drug resistance in CLL, offering a pathway towards more effective treatment strategies.
Takeaways:
– The study elucidates the interplay between CLL cells and the tumor microenvironment in driving therapy resistance and disease progression.
– AP-1 emerges as a key regulator of survival and therapy resistance in CLL, presenting a promising therapeutic target.
– Targeting both malignant B cells and reprogrammed stromal cells through AP-1 inhibition holds potential to improve patient outcomes in CLL.
– Understanding the complex interactions within the TME can guide the development of novel therapeutic approaches for CLL.
Tags: cell culture, regulatory
Read more on ajmc.com